Literature DB >> 4008606

Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses.

R D Jackson, J Wortsman, W B Malarkey.   

Abstract

This study reports the presence of a large molecular sized PRL as the major form of circulating immunoactive PRL in five women with idiopathic hyperprolactinemia and normal menses. Gel filtration patterns of serum from these patients revealed 98-100% predominance of a 150,000- to 160,000-dalton PRL in contrast to the predominance of the 22,000-dalton species in other hyperprolactinemic patients. This 150,000- to 160,000-dalton PRL was immunologically similar to the 22,000-dalton PRL, and its size on gel filtration was not altered using denaturing conditions. With reduction of disulfide bonds, there was a shift of the peak I PRL to smaller mol wt peptides. In addition, studies of one woman with idiopathic hyperprolactinemia and normal menses revealed preservation of 98% peak I predominance during physiological and pharmacological perturbations of PRL secretion. Finally, assay of the bioactivity of the large molecular sized PRL in the Nb2 rat lymphoma line revealed diminished activity compared to the 22,000-dalton species. This latter finding may help explain the maintenance of normal menses and relative lack of clinical signs in patients with this form of hyperprolactinemia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4008606     DOI: 10.1210/jcem-61-2-258

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Three cases of macroprolactinaemia.

Authors:  A O Olukoga; T L Dornan; J W Kane
Journal:  J R Soc Med       Date:  1999-07       Impact factor: 5.344

2.  Heterogeneity of serum prolactin in patients with menstrual disorder in conjunction with hyperthyroxinemia.

Authors:  H Tamai; O Mizuno; A Takaki; K Kiyohara; G Komaki; S Matsubayashi; K Kuma; L F Kumagai; S Nagataki
Journal:  J Endocrinol Invest       Date:  1991-09       Impact factor: 4.256

3.  Prevalence and reproductive manifestations of macroprolactinemia.

Authors:  Amanpreet Kaur Kalsi; Ashutosh Halder; Manish Jain; P K Chaturvedi; J B Sharma
Journal:  Endocrine       Date:  2018-09-29       Impact factor: 3.633

Review 4.  Neuroendocrine causes of amenorrhea--an update.

Authors:  Lindsay T Fourman; Pouneh K Fazeli
Journal:  J Clin Endocrinol Metab       Date:  2015-01-12       Impact factor: 5.958

5.  Hyperprolactinemia due to big big prolactin is differently detected by commercially available immunoassays.

Authors:  B Cavaco; S Prazeres; M A Santos; L G Sobrinho; V Leite
Journal:  J Endocrinol Invest       Date:  1999-03       Impact factor: 4.256

Review 6.  Control of prolactin secretion.

Authors:  G Benker; C Jaspers; G Häusler; D Reinwein
Journal:  Klin Wochenschr       Date:  1990-12-04

7.  Bioactivity and glycosylation of circulating prolactin in various physiological and pathological conditions.

Authors:  G M Gambino; P Beck-Peccoz; S Borgato; G Faglia; A Spada; L Persani
Journal:  Pituitary       Date:  1999-11       Impact factor: 4.107

8.  Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls.

Authors:  A M Jacobi; W Rohde; H D Volk; T Dörner; G R Burmester; F Hiepe
Journal:  Ann Rheum Dis       Date:  2001-03       Impact factor: 19.103

9.  Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients.

Authors:  L Vilar; M C Freitas; L A Naves; L A Casulari; M Azevedo; R Montenegro; A I Barros; M Faria; G C Nascimento; J G Lima; L H Nóbrega; T P Cruz; A Mota; A Ramos; A Violante; A Lamounier Filho; M R Gadelha; M A Czepielewski; A Glezer; M D Bronstein
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

10.  Hyperprolactinemia in asymptomatic patients is related to high molecular weight posttranslational variants or glycosylated forms.

Authors:  M Guitelman; M E Colombani-Vidal; C C Zylbersztein; L Fiszlejder; M Zeller; O Levalle; H E Scaglia
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.